Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B P Roques

Showing results (491-500 of 558) with videos related to

Pageof 56
Sort By:
European Journal of Pharmacology|August 5, 2000
Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus propertiesD M Hutcheson, F Subhan, D M Pache, et al.
Biophysical Journal|October 1, 1993
Structural and dynamic characterization of the aromatic amino acids of the human immunodeficiency virus type I nucleocapsid protein zinc fingers and their involvement in heterologous tRNA(Phe) binding: a steady-state and time-resolved fluorescence studyY Mély, E Piémont, M Sorinas-Jimeno, et al.
Life Sciences|October 18, 1982
New enkephalinase inhibitors as probes to differentiate "enkephalinase" and angiotensin-converting-enzyme active sitesB P Roques, M C Fournié-Zaluski, D Florentin, et al.
Advances in Biochemical Psychopharmacology|January 1, 1982
Rational design and biological properties of highly specific mu and delta opioid peptidesB P Roques, M C Fournié-Zaluski, G Gacel, et al.
Neurophysiologie Clinique = Clinical Neurophysiology|November 1, 1990
Novel approaches in the development of new analgesicsB P Roques, G Gacel, V Daugé, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1989
Two epitopes and one agretope map to a single HLA-A2 peptide recognized by H-2-restricted T cellsF Martinon, F Cornille, E Gomard, et al.
Journal of Medicinal Chemistry|May 1, 1988
Synthesis and biological activity of CCK26-33-related analogues modified in position 31I Marseigne, A Dor, D Bégué, et al.
European Journal of Pharmacology|June 5, 1992
Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulationA Baamonde, V Daugé, M Ruiz-Gayo, et al.
Biochemistry|July 1, 1986
Conformational analysis of cholecystokinin CCK26-33 and related fragments by 1H NMR spectroscopy, fluorescence-transfer measurements, and calculationsM C Fournié-Zaluski, J Belleney, B Lux, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 1992
Development of [125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis"M C Fournié-Zaluski, J M Soleilhac, S Turcaud, et al.
Pageof 56

Showing results (491-500 of 558) with videos related to

Sort By:
Pageof 56
European Journal of Pharmacology|August 5, 2000
Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus propertiesD M Hutcheson, F Subhan, D M Pache, et al.
Biophysical Journal|October 1, 1993
Structural and dynamic characterization of the aromatic amino acids of the human immunodeficiency virus type I nucleocapsid protein zinc fingers and their involvement in heterologous tRNA(Phe) binding: a steady-state and time-resolved fluorescence studyY Mély, E Piémont, M Sorinas-Jimeno, et al.
Life Sciences|October 18, 1982
New enkephalinase inhibitors as probes to differentiate "enkephalinase" and angiotensin-converting-enzyme active sitesB P Roques, M C Fournié-Zaluski, D Florentin, et al.
Advances in Biochemical Psychopharmacology|January 1, 1982
Rational design and biological properties of highly specific mu and delta opioid peptidesB P Roques, M C Fournié-Zaluski, G Gacel, et al.
Neurophysiologie Clinique = Clinical Neurophysiology|November 1, 1990
Novel approaches in the development of new analgesicsB P Roques, G Gacel, V Daugé, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1989
Two epitopes and one agretope map to a single HLA-A2 peptide recognized by H-2-restricted T cellsF Martinon, F Cornille, E Gomard, et al.
Journal of Medicinal Chemistry|May 1, 1988
Synthesis and biological activity of CCK26-33-related analogues modified in position 31I Marseigne, A Dor, D Bégué, et al.
European Journal of Pharmacology|June 5, 1992
Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulationA Baamonde, V Daugé, M Ruiz-Gayo, et al.
Biochemistry|July 1, 1986
Conformational analysis of cholecystokinin CCK26-33 and related fragments by 1H NMR spectroscopy, fluorescence-transfer measurements, and calculationsM C Fournié-Zaluski, J Belleney, B Lux, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 1992
Development of [125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis"M C Fournié-Zaluski, J M Soleilhac, S Turcaud, et al.
Pageof 56